David Carcedo Rodriguez

14PUBLICATIONS
41CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyPredictive and prognostic markersLiquid biopsiesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 16, 2026
Economic burden of recurrence in patients with hepatocellular carcinoma after curative-intent treatment in Spain.

|Apr 07, 2025
Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain.

Cristina Encinas, Virginia Lozano, Patrick Hlavacek

|Dec 19, 2024
Cost-effectiveness of a machine learning risk prediction model (LungFlag) in the selection of high-risk individuals for non-small cell lung cancer screening in Spain.

Juan Carlos Trujillo, Joan B Soriano, Mercè Marzo

|Oct 10, 2024
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis.

Dolores Isla, Rosa Álvarez, María Arnal

|Jan 12, 2024
Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.

Sandra Zazo, Sandra Pérez-Buira, Nerea Carvajal

|Mar 08, 2023
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.

Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Javier De Castro

Pageof 3

Frequent Collaborators

3 joint publications

Reyes Bernabé-Caro

2 joint publications

Edurne Arriola

2 joint publications

Ernest Nadal

2 joint publications

Alba Manzaneque